vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and N-able, Inc. (NABL). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $130.3M, roughly 1.4× N-able, Inc.). On growth, N-able, Inc. posted the faster year-over-year revenue change (11.8% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $20.9M). Over the past eight quarters, N-able, Inc.'s revenue compounded faster (7.0% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Able UK is a British industrial services company specialising in decommissioning of ships and offshore installations.
AMPH vs NABL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $130.3M |
| Net Profit | $24.4M | — |
| Gross Margin | 46.8% | 76.2% |
| Operating Margin | 19.4% | 10.2% |
| Net Margin | 13.3% | — |
| Revenue YoY | -1.8% | 11.8% |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $130.3M | ||
| Q3 25 | $191.8M | $131.7M | ||
| Q2 25 | $174.4M | $131.2M | ||
| Q1 25 | $170.5M | $118.2M | ||
| Q4 24 | $186.5M | $116.5M | ||
| Q3 24 | $191.2M | $116.4M | ||
| Q2 24 | $182.4M | $119.4M | ||
| Q1 24 | $171.8M | $113.7M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $1.4M | ||
| Q2 25 | $31.0M | $-4.0M | ||
| Q1 25 | $25.3M | $-7.2M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $10.8M | ||
| Q2 24 | $37.9M | $9.5M | ||
| Q1 24 | $43.2M | $7.5M |
| Q4 25 | 46.8% | 76.2% | ||
| Q3 25 | 51.4% | 77.5% | ||
| Q2 25 | 49.6% | 78.1% | ||
| Q1 25 | 50.0% | 76.6% | ||
| Q4 24 | 46.5% | 80.0% | ||
| Q3 24 | 53.3% | 82.9% | ||
| Q2 24 | 52.2% | 84.0% | ||
| Q1 24 | 52.4% | 83.9% |
| Q4 25 | 19.4% | 10.2% | ||
| Q3 25 | 13.2% | 8.8% | ||
| Q2 25 | 24.2% | 7.7% | ||
| Q1 25 | 21.9% | 1.5% | ||
| Q4 24 | 24.2% | 13.7% | ||
| Q3 24 | 29.8% | 20.5% | ||
| Q2 24 | 30.3% | 18.4% | ||
| Q1 24 | 27.9% | 18.0% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 1.1% | ||
| Q2 25 | 17.8% | -3.1% | ||
| Q1 25 | 14.8% | -6.1% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 9.2% | ||
| Q2 24 | 20.8% | 7.9% | ||
| Q1 24 | 25.1% | 6.6% |
| Q4 25 | $0.51 | $-0.04 | ||
| Q3 25 | $0.37 | $0.01 | ||
| Q2 25 | $0.64 | $-0.02 | ||
| Q1 25 | $0.51 | $-0.04 | ||
| Q4 24 | $0.74 | $0.01 | ||
| Q3 24 | $0.78 | $0.06 | ||
| Q2 24 | $0.73 | $0.05 | ||
| Q1 24 | $0.81 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $111.8M |
| Total DebtLower is stronger | $608.7M | $393.9M |
| Stockholders' EquityBook value | $788.8M | $804.7M |
| Total Assets | $1.6B | $1.4B |
| Debt / EquityLower = less leverage | 0.77× | 0.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $111.8M | ||
| Q3 25 | $276.2M | $101.4M | ||
| Q2 25 | $231.8M | $93.9M | ||
| Q1 25 | $236.9M | $94.1M | ||
| Q4 24 | $221.6M | $85.2M | ||
| Q3 24 | $250.5M | $174.4M | ||
| Q2 24 | $217.8M | $157.5M | ||
| Q1 24 | $289.6M | $139.2M |
| Q4 25 | $608.7M | $393.9M | ||
| Q3 25 | $608.6M | $331.7M | ||
| Q2 25 | $607.7M | $332.1M | ||
| Q1 25 | $603.9M | $332.6M | ||
| Q4 24 | $601.6M | $333.1M | ||
| Q3 24 | $596.4M | $333.6M | ||
| Q2 24 | $586.9M | $334.1M | ||
| Q1 24 | $594.0M | $334.5M |
| Q4 25 | $788.8M | $804.7M | ||
| Q3 25 | $776.7M | $813.4M | ||
| Q2 25 | $757.5M | $809.4M | ||
| Q1 25 | $751.3M | $775.1M | ||
| Q4 24 | $732.3M | $759.3M | ||
| Q3 24 | $727.7M | $765.0M | ||
| Q2 24 | $713.3M | $724.4M | ||
| Q1 24 | $672.4M | $709.1M |
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.6B | $1.4B | ||
| Q1 25 | $1.6B | $1.4B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $1.2B | ||
| Q1 24 | $1.6B | $1.1B |
| Q4 25 | 0.77× | 0.49× | ||
| Q3 25 | 0.78× | 0.41× | ||
| Q2 25 | 0.80× | 0.41× | ||
| Q1 25 | 0.80× | 0.43× | ||
| Q4 24 | 0.82× | 0.44× | ||
| Q3 24 | 0.82× | 0.44× | ||
| Q2 24 | 0.82× | 0.46× | ||
| Q1 24 | 0.88× | 0.47× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $25.3M |
| Free Cash FlowOCF − Capex | $24.6M | $20.9M |
| FCF MarginFCF / Revenue | 13.4% | 16.0% |
| Capex IntensityCapex / Revenue | 4.5% | 3.4% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $75.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $25.3M | ||
| Q3 25 | $52.6M | $24.0M | ||
| Q2 25 | $35.6M | $24.2M | ||
| Q1 25 | $35.1M | $19.7M | ||
| Q4 24 | $29.0M | $26.0M | ||
| Q3 24 | $60.0M | $22.0M | ||
| Q2 24 | $69.1M | $27.3M | ||
| Q1 24 | $55.3M | $4.2M |
| Q4 25 | $24.6M | $20.9M | ||
| Q3 25 | $47.2M | $17.4M | ||
| Q2 25 | $25.0M | $20.4M | ||
| Q1 25 | $24.4M | $16.4M | ||
| Q4 24 | $16.6M | $18.8M | ||
| Q3 24 | $46.2M | $18.2M | ||
| Q2 24 | $63.1M | $24.0M | ||
| Q1 24 | $46.5M | $746.0K |
| Q4 25 | 13.4% | 16.0% | ||
| Q3 25 | 24.6% | 13.2% | ||
| Q2 25 | 14.3% | 15.5% | ||
| Q1 25 | 14.3% | 13.9% | ||
| Q4 24 | 8.9% | 16.2% | ||
| Q3 24 | 24.1% | 15.7% | ||
| Q2 24 | 34.6% | 20.1% | ||
| Q1 24 | 27.1% | 0.7% |
| Q4 25 | 4.5% | 3.4% | ||
| Q3 25 | 2.8% | 5.0% | ||
| Q2 25 | 6.1% | 2.9% | ||
| Q1 25 | 6.3% | 2.8% | ||
| Q4 24 | 6.7% | 6.1% | ||
| Q3 24 | 7.2% | 3.2% | ||
| Q2 24 | 3.3% | 2.7% | ||
| Q1 24 | 5.1% | 3.0% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 17.36× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 2.04× | ||
| Q2 24 | 1.82× | 2.89× | ||
| Q1 24 | 1.28× | 0.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
NABL
| Transferred Over Time | $121.9M | 94% |
| Transferred At Point In Time | $8.4M | 6% |
| Other Revenue | $1.3M | 1% |
